Entero Therapeutics (ENTO) 10-K 30 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 30, 2020	Jun. 30, 2019
Document and Entity Information
Entity Registrant Name	AzurRx BioPharma, Inc.
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Entity Central Index Key	0001604191
Current Fiscal Year End Date	--12-31
Enity Public Float			$ 31,400,000
Entity Common Stock, Shares Outstanding		27,131,456
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Emerging Company Transition Period	false
Entity Small Business	true
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE
Entity File Number	001-37853

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 175,796	$ 1,114,343
Other receivables	2,637,303	3,172,676
Prepaid expense	595,187	512,982
Total Current Assets	3,408,286	4,800,001
Property, equipment, and leasehold improvements, net	77,391	128,854
Other Assets:
In process research & development, net	0	258,929
License agreements, net	0	311,548
Patents, net	3,407,084	0
Goodwill	1,886,686	1,924,830
Operating lease right of use asset	82,386	0
Deposits	41,047	45,233
Total Other Assets	5,417,203	2,540,540
Total Assets	8,902,880	7,469,395
Current Liabilities:
Accounts payable and accrued expense	1,754,682	2,070,396
Accounts payable and accrued expense - related party	533,428	670,095
Notes payable	444,364	255,032
Convertible debt	1,076,938	0
Other current liabilities	476,224	0
Total Current Liabilities	4,285,636	2,995,523
Contingent consideration	0	0
Total Liabilities	4,285,636	2,995,523
Stockholders' Deficit:
Convertible preferred stock - Par value $0.0001 per share; 10,000,000 shares authorized and 0 shares issued and outstanding at December 31, 2019 and 2018, respectively; liquidation preference approximates par value	0	0
Common stock - Par value $0.0001 per share; 150,000,000 and 100,000,000 shares authorized at December 31, 2019 and 2018, respectively; 26,800,519 and 17,704,925 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively.	2,680	1,771
Additional paid in capital	68,575,851	53,139,259
Accumulated deficit	(62,694,732)	(47,517,046)
Accumulated other comprehensive loss	(1,266,555)	(1,150,112)
Total Stockholders' Equity (Deficit)	4,617,244	4,473,872
Total Liabilities and Stockholders' Equity (Deficit)	$ 8,902,880	$ 7,469,395

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2018$ / sharesshares
Statement of Financial Position [Abstract]
Preferred stock shares, par value | $ / shares	$ 0.0001
Preferred stock shares, authorized	10,000,000
Preferred stock shares, outstanding	0
Common stock shares, par value | $ / shares	$ 0.0001
Common stock shares, authorized	100,000,000
Common stock shares, outstanding	17,704,925

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenue	$ 0	$ 0
Research and development expenses	8,680,669	5,771,405
General & administrative expenses	6,063,078	7,450,366
Fair value adjustment, contingent consideration	0	210,000
Total operating expense	14,743,747	13,431,771
Other:
Interest expense	433,939	101,846
Total other	433,939	101,846
Net loss	(15,177,686)	(13,533,617)
Other comprehensive (loss):
Foreign currency translation adjustment	(116,443)	(194,397)
Total comprehensive loss	$ (15,294,129)	$ (13,728,014)
Basic and diluted weighted average shares outstanding	(0.68)	(0.88)
Loss per share - basic and diluted	$ 22,425,564	$ 15,439,310

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Subscriptions Receivable	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Beginning Balance, Shares at Dec. 31, 2017	0	12,042,574
Beginning Balance, Amount at Dec. 31, 2017	$ 0	$ 1,205	$ 37,669,601	$ (1,071,070)	$ (33,983,429)	$ (955,715)	$ 1,660,592
Common stock issued from public offering, Shares		4,160,000
Common stock issued from public offering, Amount		$ 416	9,577,647				9,578,063
Common stock issued to consultants, Shares		118,818
Common stock issued to consultants, Amount		$ 12	360,759				360,771
Common stock issued to Mayloy for patents, amount							0
Common stock issued for warrant exercises, Shares		503,070
Common stock issued for warrant exercises, Amount		$ 49	1,253,623	1,071,070			2,324,742
Common stock issued for purchase of Protea assets from bankruptcy, Shares		734,463
Common stock issued for purchase of Protea assets from bankruptcy, Amount		$ 74	1,299,926				1,300,000
Convertible debt converted into common stock, Shares		26,000
Convertible debt converted into common stock, Amount		$ 3	68,670				68,673
Stock-based compensation			1,441,475				1,441,475
Restricted stock granted to employees/directors, Shares		120,000
Restricted stock granted to employees/directors, Amount		$ 12	1,038,810				1,038,822
Warrant modification			428,748				428,748
Received from stockholder in relation to warrant modification							0
Foreign currency translation adjustment						(194,397)	(194,397)
Net loss					(13,533,617)		(13,533,617)
Ending Balance, Shares at Dec. 31, 2018	0	17,704,925
Ending Balance, Amount at Dec. 31, 2018	$ 0	$ 1,771	53,139,259	0	(47,517,046)	(1,150,112)	4,473,872
Common stock issued from public offering, Shares		7,522,097
Common stock issued from public offering, Amount		$ 752	9,475,997				9,476,749
Common stock issued to consultants, Shares		190,398
Common stock issued to consultants, Amount		$ 19	209,081
Common stock issued for Mayoly for patents, shares		775,931
Common stock issued to Mayloy for patents, amount		$ 77	1,740,882				1,740,959
Common stock issued to Lincoln Park for Equity Purchase agreement, shares		487,168
Common stock issued to Lincoln Park for Equity Purchase agreement, amount		$ 49	(49)				0
Warrants issued in association with convertible debt issuances			1,081,673				1,081,673
Beneficial conversion feature on convertible debt issuances			1,359,284				1,359,284
Common stock issued for purchase of Protea assets from bankruptcy, Amount							0
Stock-based compensation							574,335
Restricted stock granted to employees/directors, Shares		120,000
Restricted stock granted to employees/directors, Amount		$ 12	607,579				607,591
Warrant modification			325,320				325,320
Received from stockholder in relation to warrant modification			61,590				61,590
Foreign currency translation adjustment						(116,443)	(116,443)
Net loss					(15,177,686)		(15,177,686)
Ending Balance, Shares at Dec. 31, 2019	0	26,800,519
Ending Balance, Amount at Dec. 31, 2019	$ 0	$ 2,680	$ 68,575,851	$ 0	$ (62,694,732)	$ (1,266,555)	$ 4,617,244

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (15,177,686)	$ (13,533,617)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	63,096	61,909
Amortization	956,950	736,537
Fixed assets written off	(7,296)	0
Fair value adjustment, contingent consideration	0	210,000
Stock-based compensation	574,335	1,441,475
Restricted stock granted to employees/directors	607,591	1,038,822
Common stock granted to consultants	210,000	360,771
Accreted interest on convertible debt	112,543	0
Accreted interest on debt discount - warrants	313,364	97,837
Warrant modification	0	428,748
Changes in assets and liabilities, net of effects of acquisition:
Other receivables	(749,859)	(2,187,903)
Prepaid expense	(85,681)	(243,330)
Right of use assets	(82,234)	0
Deposits	3,900	(15,001)
Accounts payable and accrued expense	(420,788)	741,624
Interest payable	0	(7,192)
Other liabilities	(366,329)	0
Net cash used in operating activities	(14,033,502)	(10,869,320)
Cash flows from investing activities:
Purchase of property and equipment	(24,098)	(55,473)
Purchase of Protea assets from bankruptcy	0	(250,000)
Net cash used in investing activities	(24,098)	(305,473)
Cash flows from financing activities:
Net proceeds from issuances of common stock and warrants	9,476,749	11,902,805
Proceeds from issuance of convertible debt, net	4,967,308	0
Repayments of convertible debt	(1,550,000)	(286,529)
Received from stockholder in relation to warrant modification	61,590	0
Proceeds of notes payable	498,783	286,203
Repayments of notes payable	(309,451)	(190,351)
Net cash provided by financing activities	13,144,979	11,712,128
(Decrease) Increase in cash	(921,621)	537,335
Effect of exchange rate changes on cash	(25,926)	3,537
Cash, beginning balance	1,114,343	573,471
Cash, ending balance	175,796	1,114,343
Supplemental disclosures of cash flow information:
Cash paid for interest	8,032	4,010
Non-cash investing and financing activities:
Common stock issued for purchase of Protea assets from bankruptcy that extinguished contingent consideration	0	1,300,000
Common stock issued to Mayloy for patents, amount	1,740,959	0
Warrant modification related to convertible debt issuance	$ 325,320	$ 0

The Company and Basis of Presen

The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Basis of Presentation	The Company AzurRx BioPharma, Inc. (“ AzurRx Parent ProteaBio Europe SAS ABS Company The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Non-systemic biologics are non-absorbable drugs that act locally, i.e. the intestinal lumen, skin or mucosa, without reaching an individual’s systemic circulation. The Company is focused on the development of its lead product candidate, MS1819 for the treatment of exocrine pancreatic insufficiency (“ EPI CP CF MS1819 – Phase 2a Chronic Pancreatitis Study In June 2018, the Company completed an open-label, dose escalation Phase 2a trial of MS1819 in France, Australia, and New Zealand to investigate both the safety of escalating doses of MS1819, and the efficacy of MS1819 through the analysis of each patient’s coefficient of fat absorption (“ CFA MS1819 – Phase 2 and Phase 2b Cystic Fibrosis Monotherapy Studies In October 2018, the FDA cleared the Company’s Investigational New Drug (“ IND OPTION Cross-Over Study On September 25, 2019, the Company announced positive results from the OPTION Cross-Over Study. Results showed that the primary efficacy endpoint of CFA was comparable to the CFA in a prior phase two study in patients with CP, while using the same dosage of MS1819. The dosage used in the OPTION Cross-Over Study was 2.2 grams per day, which was determined in agreement with the FDA as a bridging dose from the highest safe dose used in the Phase 2a CP dose escalation study. Although the study was not powered for statistical significance, the data demonstrated meaningful efficacy results, with approximately 50% of the patients showing CFAs high enough to reach non-inferiority with standard porcine enzyme replacement therapy (“ PERT CNA On October 17, 2019, the Company announced that the Cystic Fibrosis Foundation Data Safety Monitoring Board (the “ CFF DSMB OPTION 2 Trial The OPTION 2 Trial design will explore the use of 2.2 gram and 4.4 gram doses using enteric capsules to ensure higher levels of MS1819 release in the duodenum. The new protocol is currently under review by the FDA and a response is anticipated in March 2020. The Company expects to launch the OPTION 2 Trial as early as the second quarter of 2020, subject to regulatory approval, with completion originally anticipated by the end of 2020, however, these timelines may be delayed due to the COVID-19 epidemic. MS1819 – Phase 2 Combination Therapy Study In addition to the OPTION Cross-Over Study, the Company launched a Phase 2 multi-center clinical trial (the “ Combination Trial On October 15, 2019, the Company announced that it dosed the first patients in its Combination Trial. This study is designed to investigate the safety, tolerability and efficacy of escalating doses of MS1819 (700 mg, 1120 mg and 2240 mg per day, respectively), in conjunction with a stable dose of porcine PERTs, in order to increase the CFA and relieve abdominal symptoms. A combination therapy of PERT and MS1819 has the potential to: (i) correct macronutrient and micronutrient maldigestion; (ii) eliminate abdominal symptoms attributable to maldigestion; and (iii) sustain optimal nutritional status on a normal diet in CF patients with severe EPI. Planned enrollment is expected to include approximately 24 CF patients with severe EPI, at clinical trial sites in Hungary and additional countries in Europe, including Spain, with study completion originally anticipated by the end of 2020, however, this timeline may be delayed due to the COVID-19 epidemic. Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP The financial statements for the years ended December 31, 2019 and 2018 include the accounts of AzurRx and its wholly-owned subsidiary, AzurRx SAS. Intercompany transactions and balances have been eliminated upon consolidation. The accompanying consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception, had negative working capital at December 31, 2019 of approximately $877,000, and had an accumulated deficit of approximately $62.7 million at December 31, 2019. The Company is dependent on obtaining, and continues to pursue, additional working capital funding from the sale of securities and debt in order to continue to execute its development plan and continue operations. Without adequate working capital, the Company may not be able to meet its obligations and continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management plans to raise additional capital through additional equity and/or debt financings, including the LPC Equity Line of Credit. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Significant Accounting Policies	Use of Estimates The accompanying consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill, intangible assets and contingent consideration), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less from date of purchase to be cash equivalents. All cash balances were highly liquid at December 31, 2019 and 2018, respectively. Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At December 31, 2019 and 2018, the Company had $0 and $754,261, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions. The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros. Cyber-Related Fraud On August 8, 2019, management was advised that it was a victim of a cyber-related fraud whereby a hacker impersonated one of the Company’s key vendors to redirect payments, totaling $418,765. The Company, including the Audit Committee, completed its investigation and is reviewing all available avenues of recovery, including from the Company’s financial institution to recover the payments. As of September 30, 2019, the Company had recovered $50,858 from its financial institution but management is unable to determine the probability of recovering anything further from the cyber-related fraud. Therefore, as of December 31, 2019, the Company recorded a loss of $367,908 which is included in general and administrative (“ G&A Debt Instruments Detachable warrants issued in conjunction with debt are measured at their relative fair value, if they are determined to be equity instrument, or their fair value, if they are determined to be liability instruments, and recorded as a debt discount. Conversion features that are in the money at the commitment date constitute a beneficial conversion feature that is measured at its intrinsic value and recognized as debt discount. Debt discount is amortized as interest expense over the maturity period of the debt using the effective interest method. Contingent beneficial conversion features are recognized when the contingency has been resolved. Debt Issuance Costs Debt issuance costs are recorded as a direct reduction of the carrying amount of the related debt. Debt issuance costs are amortized over the maturity period of the related debt instrument using the effective interest method. Equity-Based Payments to Non-Employees Equity-based payments to non-employees are measured at fair value on the grant date per ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting. Fair Value Measurements The Company follows Accounting Standards Codification (“ASC” (“ASC 820” As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period. Foreign Currency Translation For foreign subsidiaries with operations denominated in a foreign currency, assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity. Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not recognized any impairment charges through December 31, 2019. Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years In Process Research & Development 12 years License Agreements 5 years Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment (“ASC 360” Income Taxes Income taxes are recorded in accordance with ASC 740, Accounting for Income Taxes (“ASC 740” The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At December 31, 2019 and 2018, the Company does not have any significant uncertain tax positions. All tax years are still open for audit. Leases Effective January 1, 2019, the Company adopted Accounting Standards Update (“ ASU Research and Development Research and development (“ R&D Stock-Based Compensation The Company’s board of directors (the “ Board (“ASC 718” For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. Sublicense Agreement As more fully discussed in Note 15, the Company entered into a sublicense agreement with TransChem, Inc. (“ TransChem Subsequent Events The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. Recent Accounting Pronouncements In January 2017, the FASB issued guidance to simplify the subsequent measurement of goodwill impairment. The new guidance eliminates the two-step process that required identification of potential impairment and a separate measure of the actual impairment. Goodwill impairment charges, if any, would be determined by reducing the goodwill balance by the difference between the carrying value and the reporting unit’s fair value (impairment loss is limited to the carrying value). This standard is effective for annual or any interim goodwill impairment tests beginning after December 15, 2019.

Fair Value Disclosures

Fair Value Disclosures	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Disclosures	Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. As of December 31, 2019 and 2018, the fair value of the Company's financial instruments were as follows: Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2019: Cash $ 175,796 $ 175,796 $ 175,796 $ - $ 175,796 Other receivables $ 2,637,303 $ - $ - $ 2,637,303 $ 2,637,303 Note payable $ 444,364 $ - $ - $ 444,364 $ 444,364 Convertible debt $ 1,076,938 $ - $ - $ 1,076,938 $ 1,076,938 At December 31, 2018: Cash $ 1,114,343 $ - $ 1,114,343 $ - $ 1,114,343 Other receivables $ 3,172,676 $ - $ - $ 3,172,676 $ 3,172,676 Note payable $ 255,032 $ - $ - $ 255,032 $ 255,032 At December 31, 2019, the fair value of other receivables approximates carrying value as these consist primarily of French R&D tax credits that are normally received the following year. At December 31, 2018, the fair value of other receivables approximates carrying value as these consist primarily of French R&D tax credits that are normally received the following year and amounts due from the Company’s former collaboration partner, Mayoly (see Note 14). The fair value of the note payable in connection with the financing of directors and officer’s liability insurance approximates carrying value due to the terms of such instruments and applicable interest rates. The convertible debt is based on its fair value less unamortized debt discount plus accrued interest through the date of reporting (see Note 9).

Other Receivables

Other Receivables	12 Months Ended
	Dec. 31, 2019
Receivables [Abstract]
Other Receivables	As of December 31, 2019 and 2018, other receivables consisted of the following: December 31, December 31, 2019 2018 R&D tax credits $ 2,566,281 $ 2,162,373 Other 71,022 1,010,303 Total other receivables $ 2,637,303 $ 3,172,676 At December 31, 2019, the research and development ( “R&D” At December 31, 2019, Other consisted of amounts due from U.S. R&D tax credits. At December 31, 2018, Other consisted primarily of amounts due from the Company’s former collaboration partner, Mayoly.

Property, Equipment, and Leaseh

Property, Equipment, and Leasehold Improvements	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property, Equipment, and Leasehold Improvements	As of December 31, 2019 and 2018, property, equipment and leasehold improvements consisted of the following: December 31, December 31, 2019 2018 Laboratory equipment $ 193,661 $ 190,406 Computer equipment 74,836 75,417 Office equipment 36,703 37,262 Leasehold improvements 35,711 29,163 Total property, plant and equipment 340,911 332,248 Less accumulated depreciation (263,520 ) (203,394 ) Property, plant and equipment, net $ 77,391 $ 128,854 Depreciation expense for the years ended December 31, 2019 and 2018 was $63,096 and $61,909, respectively. For the year ended December 31, 2019, $42,283 of depreciation is included in research and development (“ R&D G&A For the year ended December 31, 2018, $49,316 of depreciation has been reclassified to R&D expense and $12,593 of depreciation remains in G&A expense.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Patents Pursuant to the Mayoly APA entered into on March 27, 2019, in which the Company purchased all remaining rights, title and interest in and to MS1819 (see Note 14) from Mayoly, the Company recorded Patents in the amount of $3,802,745 as follows: Common stock issued at signing to Mayoly, subject to vesting $ 1,740,959 Due to Mayoly at 12/31/19 - €400,000 449,280 Due to Mayoly at 12/31/20 - €350,000 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt 1,219,386 $ 3,802,745 As of December 31, 2019 and 2018, intangible assets were as follows: December 31, December 31, 2019 2018 In process research and development $ - $ 416,600 Less accumulated amortization - (157,671 ) In process research and development, net $ - $ 258,929 License agreements $ - $ 3,398,702 Less accumulated amortization - (3,087,154 ) License agreements, net $ - $ 311,548 Patents $ 3,802,745 $ - Less accumulated amortization (395,661 ) - Patents, net $ 3,407,084 $ - Amortization expense for the years ended December 31, 2019 and 2018 was $779,895 and $736,537, respectively. For the year ended December 31, 2019, $779,895 of amortization is included R&D expense and $0 of amortization is included in G&A expense. Amortization expense for the year ended December 31, 2019 included $384,234 from in process research and development and license agreements written off as a result of the Mayoly APA. For the year ended December 31, 2018, $785,852 of amortization has been reclassified to R&D expense and $0 of amortization remains in G&A expense. Amortization expense for the year ended December 31, 2018 included $736,537 from in process research and development and license agreements written off as a result of the Mayoly APA. As of December 31, 2019, amortization expense related to patents is expected to be approximately $527,548 for each of the next five years (2020 through 2024). As of December 31, 2019 and 2018, goodwill was as follows: Goodwill Balance at January 1, 2018 $ 2,016,240 Foreign currency translation (91,410 ) Balance at December 31, 2018 1,924,830 Foreign currency translation (38,144 ) Balance at December 31, 2019 $ 1,886,686

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expense	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expense	As of December 31, 2019 and 2018, accounts payable and accrued expense consisted of the following: December 31, December 31, 2019 2018 Trade payables $ 1,683,505 $ 1,532,110 Accrued expense 71,177 285,061 Accrued payroll - 253,225 Total accounts payable and accrued expense $ 1,754,682 $ 2,070,396

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Notes Payable	On December 5, 2019, the Company entered into a 9-month financing agreement for its directors and officer’s liability insurance in the amount of $498,783 that bears interest at an annual rate of 5.461%. Monthly payments, including principal and interest, are $56,689 per month. The balance due under this financing agreement at December 31, 2019 was $444,364. On December 14, 2018, the Company entered into a 9-month financing agreement for its directors and officer’s liability insurance in the amount of $286,203 that bears interest at an annual rate of 5.99%. Monthly payments, including principal and interest, are $32,599 per month. The balance due under this financing agreement at December 31, 2018 was $255,032.

Convertible Debt

Convertible Debt	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Original Issue Discounted Convertible Notes	The ADEC Note Offering On February 14, 2019, the Company entered into a Note Purchase Agreement (the “ADEC NPA” “ADEC” “Note A” “Note B,” “ADEC Note,” “ADEC Notes” ADEC Note Offering The ADEC Notes accrue interest at a rate of 10% per annum; provided, however “2019 Tax Credit” “2020 Tax Credit” “Maturity Dates” Each of the ADEC Notes is convertible, at ADEC’s option, into shares of Common Stock, at a conversion price equal to $2.50 per share; provided however ADEC Note Conversion Shares As additional consideration for entering into the ADEC NPA, the Company entered into a warrant amendment agreement, whereby the Company agreed to reduce the exercise price of 1,009,565 outstanding warrants previously issued by the Company to ADEC and its affiliates (the “ADEC Warrants” ADEC Warrant Amendment In connection with the above transaction, the Company also entered into a registration rights agreement with ADEC. The registration statement was filed with the Securities and Exchange Commission (“ SEC During the year ended December 31, 2019, the Company recognized $311,116 of interest expense related to the ADEC Notes, including amortization of debt discount of $206,963 related to the ADEC Warrant Amendment. In December 2019, the Company repaid $1,550,000 principal amount of the ADEC Notes and in January 2020 repaid the remaining principal balance of $450,000 plus outstanding accrued interest of $104,153. December 2019 Senior Convertible Promissory Note Offering On December 20, 2019, the Company began an offering of (i) Senior Convertible Promissory Notes (each a “ Promissory Note Promissory Notes Note Investors Note Warrants Promissory Promissory Note Offering On December 20, 2019, December 24, 2019, December 30, 2019, and December 31, 2019, the Company issued Promissory Notes to the Note Investors in the aggregate principal amount of $3,386,300. The Promissory Notes mature on September 20, 2020, accrue interest at a rate of 9% per annum, and are convertible, at the sole option of the holder, into shares of Common Stock (the “ Promissory Note Conversion Shares Conversion Option Prepayment Option As additional consideration for the execution of the Promissory NPA, each Note Investor also received Note Warrants to purchase that number of shares of Common Stock equal to one-half (50%) of the Promissory Note Conversion Shares issuable upon conversion of the Promissory Notes (the “ Warrant Shares RRA In connection with the four closings in December 2019 of the Promissory Placement Agent Warrants The Company determined the Prepayment Option feature represents a contingent call option. The Company evaluated the Prepayment Option in accordance with ASC 815-15-25. The Company determined that the Prepayment Option feature is clearly and closely related to the debt host instrument and is not an embedded derivative requiring bifurcation. Additionally, the Company determined the Conversion Option represents an embedded call option. The Company evaluated the Conversion Option in accordance with ASC 815-15-25. The Company determined that the Conversion Option feature meets the scope exception from ASC 815 and is not an embedded derivative requiring bifurcation. The Company evaluated the Promissory Notes for a beneficial conversion feature in accordance with ASC 470-20. The Company determined that at each commitment date the effective conversion price was below the closing stock price (market value), and the Convertible Notes contained a beneficial conversion feature. Pursuant to the December 2019 closings of the Promissory Note Offering, the principal amount of $3,386,300 was first allocated based on the relative fair value of the Promissory Notes and the Note Warrants. The fair value of the Note Warrants amounted to $912,648. Then the beneficial conversion feature was calculated, which amounted to $1,359,284. The Company incurred debt issuance costs of $588,017 related to the offering. The initial carrying value of the Promissory Notes issued amounted to $526,351. During the year ended December 31, 2019, the Company recognized $114,791 of interest expense related to these Promissory Notes, including amortization of debt discount related to the value of the Note Warrants of $33,669, amortization of the beneficial conversion feature of $51,529, amortization of debt discount related to debt issuance costs of $21,203, and accrued interest expense of $8,390. As of December 31, 2019 and 2018, convertible debt consisted of the following: Total Promissory Notes ADEC Notes Total December 31, December 31, December 31, December 31, 2019 2019 2019 2018 Convertible debt $ 3,836,300 $ 3,386,300 $ 450,000 $ - Unamortized debt discount - revalued warrants (118,356 ) - (118,356 ) - Unamortized debt discount - warrants (878,979 ) (878,979 ) - - Unamortized debt discount - BCF (1,307,755 ) (1,307,755 ) - - Unamortized debt discount - debt issuance costs (566,815 ) (566,815 ) - - Accrued interest 112,543 8,390 104,153 - Total convertible debt $ 1,076,938 $ 641,141 $ 435,797 $ - LPC OID Debenture On April 11, 2017, the Company entered into a Note Purchase Agreement with Lincoln Park Capital Fund, LLC ( “LPC” “OID Debenture” On July 11, 2018, the Company paid off the remaining amount of $286,529 due under the terms of this OID Debenture. For the year ended December 31, 2018, the Company recorded $97,837 of interest expense related to the amortization of the debt discount and beneficial conversion feature related to the warrant features of the OID Debenture.

Equity, Common stock and Incent

Equity, Common stock and Incentive plan	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Equity, Common Stock, and Incentive plan	On December 19, 2019, the Company held its Annual Meeting of Stockholders (the “ Annual Meeting Reverse Split Common Stock The Company had 26,800,519 and 17,704,925 shares of its Common Stock issued and outstanding at December 31, 2019 and 2018, respectively. The holders of our Common Stock are entitled to one vote per share. In addition, the holders of our Common Stock will be entitled to receive ratably such dividends, if any, as may be declared by our Board out of legally available funds; however 2014 Equity Incentive Plan The Company’s Board and stockholders adopted and approved the Amended and Restated 2014 Omnibus Equity Incentive Plan (the “ 2014 Plan As Converted Shares The Company issued an aggregate of 1,193,500 and 539,000 stock options, during the years ended December 31, 2019 and 2018, respectively, under the 2014 Plan (see Note 13). As of December 31, 2019, there were an aggregate of 3,584,986 total shares available under the 2014 Plan, of which 1,677,500 are issued and outstanding, 632,667 shares are reserved subject to issuance of restricted stock and RSUs and 1,274,819 shares are available for potential issuances. The Company may issue securities outside of the 2014 Plan. Series A Convertible Preferred Stock Pursuant to a stock purchase agreement with the Protea Group, on June 13, 2014, the Company issued 100 shares of Series A Convertible Preferred Stock ( “Series A Preferred” The terms of the Series A Preferred are described below: Voting The Series A Preferred holders are entitled to vote, together with the holders of Common Stock as one class, on all matters to which holders of Common Stock shall be entitled to vote, in the same manner and with the same effect as the Common Stock holders with the same number of votes per share that equals the number of shares of Common Stock into which the Series A Preferred is convertible at the time of such vote. Dividends The holders of the Series A Preferred shall be entitled to receive dividends, when, as, and if declared by the board of directors, ratably with any declaration or payment of any dividend on Common Stock. To date there have been no dividends declared or paid by the board of directors. Liquidation The holders of the Series A Preferred shall be entitled to receive, before and in preference to, any distribution of any assets of the Company to the holders of Common Stock, an amount equal to $0.0001 per share, plus any declared but unpaid dividends. The liquidation preference approximates par value as of December 31, 2019 and 2018, respectively. Conversion The Series A Preferred was initially convertible into 33% of the issued and outstanding shares of Common Stock on a fully diluted basis, assuming the conversion, exercise, or exchange for shares of Common Stock of all convertible securities issued and outstanding immediately prior to such conversion, including the Series A Preferred stock, all outstanding warrants and options, and all outstanding convertible debt, notes, debentures, or any other securities which are convertible, exercisable, or exchangeable for shares of Common Stock. The Series A Preferred was convertible at the holder’s option any time commencing on the one-year anniversary of the initial issuance date. The Series A Preferred was subject to mandatory conversion at any time commencing on the one-year anniversary of the initial issuance date upon the vote or written consent by the holders of a majority of the Series A Preferred then outstanding or upon the occurrence of certain triggering events, including a public offering coupled with an equity-linked financing with an offering price that values the Company prior to consummation of such financing at not less than $12,000,000 and the aggregate gross proceeds to the Company (before deduction of underwriting discounts and registration expenses) are not less than $6,000,000. On November 11, 2015, the Company and the Protea Group agreed that the Series A Preferred would be convertible into 2,439,365 shares of Common Stock. During the year ended December 31, 2016, Protea Group converted all shares of Series A Preferred into Common Stock. LPC Equity Line of Credit On November 13, 2019, the Company entered into a purchase agreement (the “ LPC Purchase Agreement LPC Registration Rights Agreement LPC Equity Line of Credit Commitment Shares Under the LPC Purchase Agreement, on any business day over the term of the LPC Purchase Agreement, the Company has the right, in its sole discretion, to present LPC with a purchase notice (each, a “ Purchase Notice Regular Purchase Purchase Price ● the lowest sale price of Common Stock on the purchase date; and; ● the average of the three lowest closing sale prices for the Common Stock during the ten consecutive business days ending on the business day immediately preceding the purchase date of such shares; In addition, on any date on which the Company submits a Purchase Notice to LPC, the Company also has the right, in its sole discretion, to present LPC with an accelerated purchase notice (each, an “ Accelerated Purchase Notice Accelerated Purchase Accelerated Purchase Measurement Period ● 97% of the volume weighted average price of the Company’s common stock during the applicable Accelerated Purchase Measurement Period on the applicable Accelerated Purchase date; and ● the closing sale price of Common Stock on the applicable Accelerated Purchase Date. The Company may also direct LPC on any business day on which an Accelerated Purchase has been completed and all of the shares to be purchased thereunder have been properly delivered to LPC in accordance with the LPC Purchase Agreement, to purchase an amount of stock (the “ Additional Accelerated Purchase Additional Accelerated Purchase Measurement Period ● 97% of the volume weighted average price of the Company’s common stock during the applicable Additional Accelerated Purchase Measurement Period on the applicable Additional Accelerated Purchase date; and ● the closing sale price of Common Stock on the applicable Additional Accelerated Purchase. Common Stock Issuances 2019 Issuances During the year ended December 31, 2019, pursuant to the Mayoly APA, the Company issued Mayoly 400,481 shares of Common Stock (the “ Closing Payment Shares During the year ended December 31, 2019, the Company issued an aggregate of 92,995 shares of its Common Stock to consultants as payment of $135,000 of accounts payable and 97,403 shares of its Common Stock to a consultant with a grant date fair value of $75,000 for services provided. During the year ended December 31, 2019, the Company issued an aggregate of 120,000 shares of its Common Stock to outside members of its Board as payment of Board fees with an aggregate grant date fair value of $173,400, that was recorded as part of G&A expense. April 2019 Registered Direct Public Offering In April 2019, the Company completed a public offering of 1,294,930 shares of Common Stock at a public offering price of $2.13 per share, resulting in net proceeds of approximately $2,500,000, after deducting the selling agent fees and other offering expense payable by the Company (the “ April 2019 Public Offering In connection with the April 2019 Public Offering, the Company entered into a selling agent agreement, pursuant to which the Company paid (i) a cash fee equal to 7% of the aggregate gross proceeds of the April 2019 Public Offering, and (ii) issued warrants to purchase an aggregate of 38,848 shares of Common Stock (the “ April 2019 Selling Agent Warrants May 2019 Registered Direct Public Offering In May 2019, the Company completed a second public offering of 1,227,167 shares of Common Stock at a public offering price of $2.35 per share, resulting in net proceeds of approximately $2,550,000, after deducting the selling agent fees and other offering expense payable by the Company (the “ May 2019 Public Offering In connection with the May 2019 Public Offering, the Company entered into a selling agent agreement, pursuant to which the Company (i) paid a cash fee equal to 7.0% of the aggregate gross proceeds of the May 2019 Public Offering, and (ii) issued warrants to purchase up to an aggregate of 36,815 shares of Common Stock (the “ May 2019 Selling Agent Warrants July 2019 Underwritten Public Offering In July 2019, the Company completed an underwriting public offering of 5,000,000 shares of Common Stock at a public offering price of $1.00 per share, resulting in net proceeds of approximately $4,500,000, after deducting the underwriting discount, and other offering expense payable by the Company (the “ July 2019 Public Offering SEC In connection with the July 2019 Public Offering, the Company entered into an underwriting agreement, pursuant to which the Company (i) paid an cash fee equal to 7.0% of the aggregate gross proceeds of the July 2019 Public Offering, and (ii) issued warrants to purchase up to an aggregate of 200,000 shares of Common Stock (the “ May 2019 Underwriting Warrants Purchase Agreement with Lincoln Park Capital Fund, LLC In connection with entering into the LPC Purchase Agreement on November 13, 2019, the Company issued LPC 487,168 shares of Common Stock (the “ Commitment Shares 2018 Issuances During the year ended December 31, 2018, the Company issued an aggregate of 120,000 shares of its Common Stock to outside members of its Board as payment of Board fees with an aggregate grant date fair value of $306,300, that was recorded as part of G&A expense. Restricted Stock and Restricted Stock Units During the year ended December 31, 2019, pursuant to the Mayoly APA, the Company issued Mayoly 200,240 shares of restricted Common Stock that vested on December 31, 2019 and 175,210 shares of restricted Common Stock that vest on December 31, 2020. During the year ended December 31, 2019, the Company recognized $823,858 as part of stockholders’ equity. During the year ended December 31, 2019, the Company issued James Sapirstein, its new Chief Executive Officer a restricted stock unit (“ RSU During the year ended December 31, 2019, an aggregate of 188,333 unvested shares of restricted Common Stock that were issued to former executives were canceled with a total grant date fair value of approximately $499,832 due to their resignations from the Company. During the year ended December 31, 2019, an aggregate of 92,167 unvested shares of restricted Common Stock, subject to milestone-based vesting, vested with a total grant date fair value of $280,187. 58,833 of these 92,167 restricted shares of Common Stock with a total grant date fair value of $178,852 vested during the year ended December 31, 2019 due to the Company dosing the first patients in the OPTION Cross-Over Study for MS1819 in CF patients. 33,334 of these 138,835 restricted shares of Common Stock having a total grant date fair value of $101,335 vested during the year ended December 31, 2019 due to the Company completing enrollment in the OPTION Cross-Over Study for MS1819 in CF patients. The Company recognized $280,187 as stock expense during the year ended December 31, 2019 for the vesting of these shares of restricted Common Stock. During the year ended December 31, 2019, an aggregate of 48,668 unvested shares of restricted Common Stock, subject to time-based vesting, vested with a total grant date fair value of $154,004. The Company recognized $154,004 as stock expense during the year ended December 31, 2019 for the vesting of these shares of restricted Common Stock. As of December 31, 2019, the Company had an aggregate unrecognized restricted Common Stock expense of $154,689, of which $50,689 will be recognized over the average remaining vesting term of 0.65 years and $104,000 will be recognized when vesting of certain milestones will be probable. During the year ended December 31, 2018, an aggregate of 51,000 shares of restricted Common Stock were granted and accrued to employees with a total grant date fair value of $155,040. During the year ended December 31, 2018, 100,000 shares of restricted Common Stock were granted and accrued to Johan (Thijs) Spoor, the former Chief Executive Officer, subject to milestone-based vesting with a total grant date fair value of $304,000. During the year ended December 31, 2018, 100,000 shares of restricted Common Stock were granted and accrued to Johan (Thijs) Spoor, the former Chief Executive Officer, subject to time-based vesting over three years with a grant date fair value of $304,000. During the year ended December 31, 2018, The Company issued an aggregate of 192,067 shares of restricted Common Stock were granted or accrued to employees and consultants with a total grant date fair value of $682,271. During the year ended December 31, 2018, 5,000 shares of restricted Common Stock were canceled with a grant date fair value of $15,200. During the year ended December 31, 2018, an aggregate of 315,235 shares of restricted Common Stock vested with a total grant date fair value of $1,093,293. An aggregate of 158,833 of these shares of restricted Common Stock with a total grant date fair value of $603,852 vested due to the Company achieving certain clinical milestones for MS1819.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2019
Warrants Abstract
Warrants	For the year ended December 31, 2019, in connection with the December 2019 closings of the Promissory Note Offering, the Company issued Note Warrants to investors to purchase an aggregate of 1,745,538 shares of Common Stock with the issuance of the Promissory Notes as referenced in Note 9. These Note Warrants were issued between December 20, 2019 and December 31, 2019, are exercisable commencing six (6) months following the issuance date at $1.07 per share and expire five years from issuance. The total grant date fair value of these warrants was determined to be approximately $1,250,398, as calculated using the Black-Scholes model, and were recorded as a debt discount based on their relative fair value. For the year ended December 31, 2019, in connection with the December 2019 closings of the Promissory Note Offering, the Company issued placement agent warrants to purchase an aggregate of 244,372 shares of Common Stock. These placement agent warrants were issued between December 20, 2019 and December 31, 2019, vested immediately, are exercisable at $1.21 per share and expire five years from issuance. The total grant date fair value of these placement agent warrants was determined to be approximately $169,025, as calculated using the Black-Scholes model, and was charged to debt discount that will be amortized over the life of the debt. During the year ended December 31, 2019, in connection with the April 2019 Public Offerings, the Company issued the April 2019 Selling Agent Warrants to purchase an aggregate of 38,848 shares of Common Stock. The April 2019 Selling Agent Warrants will become exercisable April 2, 2020, expire on April 2, 2024 and have an exercise price of $2.55 per share. The total grant date fair value of these investment banking warrants was determined to be approximately $60,991, as calculated using the Black-Scholes model, and had no effect on expenses or stockholders’ equity. During the year ended December 31, 2019, in connection with the May 2019 Public Offerings, the Company issued the May 2019 Selling Agent Warrants to purchase an aggregate of 36,815 shares of Common Stock. The May 2019 Selling Agent Warrants will become exercisable on May 9, 2020, expire on May 9, 2024 and have an exercise price of $2.82 per share. The total grant date fair value of these investment banking warrants was determined to be approximately $55,591, as calculated using the Black-Scholes model, and had no effect on expenses or stockholders’ equity. During the year ended December 31, 2019, in connection with the July 2019 Public Offerings, the Company issued the July 2019 Underwriting Warrants to purchase an aggregate of 200,000 shares of Common Stock. The July 2019 Underwriting Warrants are exercisable immediately, expire on July 17, 2024 and have an exercise price of $1.25 per share. The total grant date fair value of these investment banking warrants was determined to be approximately $116,600, as calculated using the Black-Scholes model, and had no effect on expenses or stockholders’ equity. In February 2019, as additional consideration for issuing the ADEC Notes and pursuant to the ADEC Warrant Amendment, the Company agreed to reduce the exercise price of certain outstanding warrants previously issued by the Company to ADEC and its affiliates (see Note 9). During the year ended December 31, 2018, warrants to purchase an aggregate of 244,400 shares of Common Stock were issued to investment bankers in connection with the May 2018 Public Offering. These investment banking warrants were issued on May 3, 2018, vested immediately, are exercisable at prices ranging from $2.25 to $2.75 per share and expire five years from issuance. The grant date fair value of these investment banking warrants was determined to be approximately $416,426, as calculated using the Black-Scholes model, and had no effect on expenses or stockholders’ equity. In January 2018, the Company offered certain warrant holders the opportunity to exercise their warrants at a reduced strike price of $2.50, and if so elected, would also have the opportunity to reprice other warrants that they continued to hold unexercised to $3.25. The offer, which was effective on January 12, 2018, was for the repricing only and did not modify the life of the warrants. Warrant holders of approximately 503,000 shares of Common Stock exercised their warrants and had other warrants modified on approximately 197,000 shares of Common Stock, which resulted in a charge of approximately $429,000 in the year ended December 31, 2018. Warrant transactions for the years ending December 31, 2019 and 2018 were as follows: Exercise Weighted Price Per Average Warrants Share Exercise Price Warrants outstanding and exercisable at January 1, 2018 3,371,385 $ 3.17 - $7.37 $ 5.28 Granted during the period 244,400 $ 2.55 - $2.75 $ 2.58 Expired during the period - - - Exercised during the period (503,070 ) $ 2.50 $ 2.50 Warrants outstanding and exercisable at December 31, 2018 3,112,715 $ 2.55 - $7.37 $ 4.83 Warrants outstanding and exercisable at January 1, 2019 3,112,715 $ 2.55 - $7.37 $ 4.83 Granted during the period 2,265,573 $ 1.07 - $2.82 $ 1.15 Expired during the period - - - Exercised during the period - - - Warrants outstanding and exercisable at December 31, 2019 5,378,288 $ 1.25 - $7.37 $ 2.53 Warrants exercisable at December 31, 2019 were as follows: Number of Weighted Average Weighted Shares Under Remaining Contract Average Exercise Price Warrants Life in Years Exercise Price $ 1.07 - $1.99 3,199,475 3.95 $ 2.00 - $2.99 320,063 3.57 $ 3.00 - $3.99 636,972 2.31 $ 4.00 - $4.99 196,632 2.01 $ 5.00 - $5.99 805,476 2.13 $ 6.00 - $6.99 187,750 1.76 $ 7.00 - $7.37 31,920 0.96 Total 5,378,288 3.30 $ 2.53 The weighted average fair value of warrants granted during the years ended December 31, 2019 and 2018, was $0.71 and $1.70 per share, respectively. The grant date fair values were calculated using the Black-Scholes model with the following weighted average assumptions: December 31, December 31, 2019 2018 Expected life (in years) 5 5 Volatility 71 - 80 % 84 % Risk-free interest rate 1.64 - 2.37 % 2.70 % Dividend yield - % - %

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
Stock Options	Under the 2014 Plan, the fair value of stock options granted is estimated on the grant date using the Black-Scholes model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the volatility of the Common Stock price and the assumed risk-free interest rate. The Company recognizes stock-based compensation expense for only those shares expected to vest over the requisite service period of the award. No compensation cost is recorded for options that do not vest and the compensation cost from vested options, whether forfeited or not, is not reversed. During the year ended December 31, 2019, the Company issued stock options to purchase an aggregate of 120,000 shares of Common Stock with a strike price of $1.75 per share and a term of five years to certain Board members that vest quarterly over one (1) year. These options had a total fair value of approximately $126,000, as calculated using the Black-Scholes model and were recorded as stock-based compensation. During the year ended December 31, 2019, the Company issued stock options to purchase 150,000 shares of Common Stock with a strike price of $1.75 per share and a term of five years to Johan (Thijs) Spoor, the former Chief Executive Officer that vest upon the completion of enrollment of the next trial of MS1819 in the U.S. These stock options had a grant date fair value of approximately $151,950, as calculated using the Black-Scholes model. These unvested stock options were cancelled as a result of Mr. Spoor’s resignation. During the year ended December 31, 2019, the Company issued stock options to purchase 100,000 shares of Common Stock with a strike price of $1.75 per share and a term of five years to Maged Shenouda, the former Chief Financial Officer that vest upon the completion of enrollment of the next trial of MS1819 in the U.S. These stock options had a grant date fair value of approximately $101,300, as calculated using the Black-Scholes model. These unvested stock options were cancelled as a result of Mr. Shenouda’s resignation. During the year ended December 31, 2019, the Company issued stock options to purchase an aggregate of 523,500 shares of Common Stock with a strike price of $1.75 per share and a term of five years to certain employees with milestone-based vesting based on certain clinical milestones for MS1819. These options had a total grant date fair value of approximately $549,675, as calculated using the Black-Scholes model. 454,250 of these stock options will vest upon enrollment completion of the next MS1819 clinical trial in the U.S. for CF (the OPTION 2 Trial), and 69,250 of these stock options will vest upon enrollment completion of the ongoing Combination Trial in Europe. The Company will recognize the expense related to these milestones when the milestones become probable. The weighted average fair value of stock options granted to employees during the year ended December 31, 2019 was $0.89 per share. During the year ended December 31, 2019, stock options to purchase an aggregate of 304,500 shares of Common Stock vested having a fair value of $574,335. 242,000 of these stock options with a fair value of $501,666 vested due to the Company achieving certain clinical milestones for MS1819. During the year ended December 31, 2019, stock options to purchase an aggregate of 510,000 shares of Common Stock were canceled with strike prices ranging from of $1.75 to $4.48 per share. During the year ended December 31, 2018, stock options to purchase an aggregate of 539,000 shares of Common Stock were granted with a strike price of $3.04 per share and a term of five years. During the year ended December 31, 2018, stock options to purchase an aggregate of 600,750 shares of Common Stock vested having a fair value of $1,441,475. Stock options to purchase an aggregate of 570,750 shares of Common Stock with a fair value of $1,325,404 vested due to the Company achieving certain clinical milestones for MS1819. During the year ended December 31, 2018, 90,000 stock options were canceled with exercise prices ranging from of $3.04 to $3.60. The weighted average fair value of stock options granted to employees during the year ended December 31, 2018 was $2.07 per share. The fair values were estimated on the grant dates using the Black-Scholes option-pricing model with the following weighted-average assumptions: December 31, December 31, 2019 2018 Contractual term (in years) 5 - 10 5 Volatility 72% - 75 % 85 % Risk-free interest rate 1.54% - 1.84 % 2.82 % Dividend yield - % - % The expected term of the options is based on expected future employee exercise behavior. Volatility is based on the historical volatility of the Company’s common stock if available or of several public entities that are similar to the Company. The Company bases volatility this way because it may not have sufficient historical transactions in its own shares on which to solely base expected volatility. The risk-free interest rate is based on the U.S. Treasury rates at the date of grant with maturity dates approximately equal to the expected term at the grant date. The Company has not historically declared any dividends and does not expect to in the future. The Company realized no income tax benefit from stock option exercises in each of the periods presented due to recurring losses and valuation allowances. During the years ended December 31, 2019 and 2018, stock option activity under the 2014 Plan was as follows: Number Average Remaining Contract Intrinsic of Shares Exercise Price Life in Years Value Stock options outstanding at January 1, 2018 545,000 $ 4.05 7.13 $ - Granted during the period 539,000 $ 3.04 5.00 $ - Expired during the period - - Canceled during the period (90,000 ) $ 3.26 4.41 $ - Exercised during the period - - Stock options outstanding at December 31, 2018 994,000 $ 3.58 5.42 $ - Exercisable at December 31, 2018 749,500 $ 3.74 5.71 $ - Non-vested stock options outstanding at January 1, 2018 387,500 $ 3.89 6.39 $ - Granted during the period 539,000 $ 3.04 5.00 $ - Vested during the period (600,750 ) $ 3.50 5.00 $ - Expired during the period - - Canceled during the period (81,250 ) $ 3.26 4.41 $ - Exercised during the period - - Non-vested stock options outstanding at December 31, 2018 244,500 $ 3.05 4.53 $ - Stock options outstanding at January 1, 2019 994,000 $ 3.58 5.42 $ - Granted during the period 1,193,500 $ 1.44 5.79 $ - Expired during the period - - Canceled during the period (510,000 ) $ 2.80 4.50 $ - Exercised during the period - - Stock options outstanding at December 31, 2019 1,677,500 $ 2.17 5.37 $ - Exercisable at December 31, 2019 794,000 $ 3.36 4.04 $ - Non-vested stock options outstanding at January 1, 2019 244,500 $ 3.05 4.53 $ - Granted during the period 1,193,500 $ 1.44 5.79 $ - Vested during the period (304,500 ) $ 2.79 3.72 $ - Expired during the period - - Canceled during the period (250,000 ) $ 1.75 4.45 $ - Exercised during the period - - Non-vested stock options outstanding at December 31, 2019 883,500 $ 1.33 6.26 $ - As of December 31, 2019, the Company had unrecognized stock-based compensation expense of $733,575. $63,000 of this unrecognized expense will be recognized over the average remaining vesting term of the options of 0.50 years. $517,262 of this unrecognized expense will vest upon enrollment completion next MS1819 clinical trial in the U.S. for CF (the OPTION 2 Trial). $72,713 of this unrecognized expense will vest upon enrollment completion of the ongoing Combination Trial in Europe. $40,300 of this unrecognized expense vests upon the Company initiating a Phase III clinical trial in the U.S. for MS1819. $40,300 of this unrecognized expense vests upon initiating a U.S. Phase I clinical trial for any product other than MS1819. The Company will recognize the expense related to these milestones when the milestones become probable.

Interest Expense

Interest Expense	12 Months Ended
	Dec. 31, 2019
Interest Expense [Abstract]
Interest Expense	During the years ended December 31, 2019, the Company incurred $433,939 of interest expense, including amortization of debt discount of $425,907 and miscellaneous interest expense of $8,032. During the years ended December 31, 2018, the Company incurred $101,846 of interest expense, including amortization of debt discount of $97,837 and miscellaneous interest expense of $4,010.

Agreements

Agreements	12 Months Ended
	Dec. 31, 2019
Agreements
Agreements	Mayoly Agreement During the years ended December 31, 2019 and 2018, the Company charged $403,020 and $621,724, respectively, to Mayoly under the JDLA that was in effect during both periods. On March 27, 2019, the Company entered into the Mayoly APA pursuant to which the Company assumed the JDLA and purchased substantially all remaining rights, title and interest in and to MS1819 (see “Recent Developments” above). INRA Agreement In February 2006, Mayoly and INRA TRANSFERT, on behalf of INRA and CNRS (French government research centers), entered into a Usage and Cross-Licensing Agreement granting Mayoly exclusive worldwide rights to exploit Yarrowia lipolytica TransChem Sublicense On August 7, 2017, the Company entered into a sublicense agreement with TransChem, pursuant to which TransChem granted the Company an exclusive license to patents and patent applications relating to Helicobacter pylori 5’methylthioadenosine nucleosidase inhibitors (the “TransChem Licensed Patents” “TransChem Sublicense Agreement” On March 12, 2020, the Company provided TransChem with 60 days’ notice of its intent to terminate the TransChem Sublicense Agreement. Employment Agreements James Sapirstein Effective October 8, 2019, the Company entered into an employment agreement with Mr. Sapirstein to serve as its President and Chief Executive Officer for a term of three years, subject to further renewal upon agreement of the parties. The employment agreement with Mr. Sapirstein provides for a base salary of $450,000 per year. In addition to the base salary, Mr. Sapirstein is eligible to receive (i) a cash bonus of up to 40% of his base salary on an annual basis, based on certain milestones that are yet to be determined; (ii) 1% of net fees received by the Company upon entering into license agreements with any third-party with respect to any product current in development or upon the sale of all or substantially all assets of the Company; (iii) a grant of 200,000 restricted shares (RSUs) of Common Stock which are subject to vest as follows (a) 100,000 shares upon the first commercial sale of MS1819 in the U.S., and (b) 100,000 shares upon the total market capitalization of the Company exceeding $1.0 billion for 20 consecutive trading days; (iv) a grant of 300,000 10-year stock options to purchase shares of Common Stock with a strike price equal to $0.52 per share, which are subject to vest as follows (a) 50,000 shares upon the Company initiating its next Phase II clinical trial in the U.S. for MS1819, (b) 50,000 shares upon the Company completing its next or subsequent Phase II clinical trial in the U.S. for MS1819, (c) 100,000 shares upon the Company initiating a Phase III clinical trial in the U.S. for MS1819, and (d) 100,000 shares upon the Company initiating a Phase I clinical trial in the U.S. for any product other than MS1819. Mr. Sapirstein is entitled to receive 20 days of paid vacation, participate in full employee health benefits and receive reimbursement for all reasonable expenses incurred in connection with his services to the Company. In the event that Mr. Sapirstein’s employment is terminated by the Company for Cause, as defined in his employment agreement, or by Mr. Sapirstein voluntarily, then he will not be entitled to receive any payments beyond amounts already earned, and any unvested equity awards will terminate. In the event that Mr. Sapirstein’s employment is terminated as a result of an Involuntary Termination Other than for Cause, as defined in his employment agreement, Mr. Sapirstein will be entitled to receive the following compensation: (i) severance in the form of continuation of his salary (at the Base Salary rate in effect at the time of termination, but prior to any reduction triggering Good Reason) for a period of 12 months following the termination date; (ii) payment of Executive’s premiums to cover COBRA for a period of 12 months following the termination date; and (iii) a prorated annual bonus. Daniel Schneiderman Effective January 2, 2020, the Company entered into an employment agreement with Mr. Schneiderman to serve as the Company’s Chief Financial Officer for a term of three years, subject to further renewal upon agreement of the parties. The employment agreement with Mr. Schneiderman provides for a base salary of $285,000 per year. In addition to the base salary, Mr. Schneiderman is eligible to receive (a) an annual milestone cash bonus based on certain milestones that will be established by the Company’s Board or the Compensation Committee, and (b) a grant of stock options to purchase 335,006 shares of Common Stock with a strike price of $1.03 per share, which shall vest in three equal portions on each anniversary date of the Effective Date commencing on the first anniversary date of the agreement. Mr. Schneiderman is entitled to receive 20 days of paid vacation, participate in full employee health benefits and receive reimbursement for all reasonable expenses incurred in connection with his service to the Company. The Company may terminate Mr. Schneiderman’s employment agreement at any time, with or without Cause, as such term is defined in his employment agreement. In the event that Mr. Schneiderman’s employment is terminated by the Company for Cause, as defined in his employment agreement, or by Mr. Schneiderman voluntarily, then he will not be entitled to receive any payments beyond amounts already earned, and any unvested equity awards will terminate. If the Company terminates his employment agreement without Cause, not in connection with a Change of Control, as such term is defined in his employment agreement, Mr. Schneiderman will be entitled to (i) all salary owed through the date of termination; (ii) any unpaid annual milestone bonus; (iii) severance in the form of continuation of his salary for the greater of a period of 6 months following the termination date or the remaining term of the employment agreement; (iv) payment of premiums to cover COBRA for a period of 6 months following the termination date; (v) a prorated annual bonus equal to the target annual milestone bonus, if any, for the year of termination multiplied by the formula set forth in the agreement. If the Company terminates his employment agreement without Cause, in connection with a Change of Control, as such term is defined in his employment agreement, Mr. Schneiderman will be entitled to the above and immediate accelerated vesting of any unvested options or other unvested awards. Dr. James E. Pennington Effective May 28, 2018, the Company entered into an employment agreement with Mr. Pennington to serve as its Chief Medical Officer. The employment agreement with Dr. Pennington provides for a base annual salary of $250,000. In addition to his salary, Dr. Pennington is eligible to receive an annual milestone bonus, awarded at the sole discretion of the Board based on his attainment of certain financial, clinical development, and/or business milestones established annually by the Board or Compensation Committee. The Company may terminate Mr. Pennington’s employment agreement at any time, with or without Cause, as such term is defined in his employment agreement. In the event of termination by the Company other than for Cause, Dr. Pennington is entitled to three months’ severance payable over such period. In the event of termination by the Company other than for Cause in connection with a Change of Control as such term is defined in his employment agreement, Dr. Pennington will receive six months’ severance payable over such period. On June 28, 2018, Mr. Pennington was granted stock options to purchase 75,000 shares of Common Stock with a strike price equal to $3.04 per share, issuable pursuant to the 2014 Plan, subject to vesting conditions as follows: (i) 50% upon U.S. acceptance of an IND for MS1819, and (ii) 50% upon the first CF patient dosed with MS1819 anywhere in the world. On June 13, 2019, Mr. Pennington was granted stock options to purchase 110,000 shares of Common Stock with a strike price equal to $1.75 per share, issuable pursuant to the 2014 Plan, that vest upon the completion of enrollment of the next MS1819 clinical trial in the U.S. for CF (the OPTION 2 Trial). On June 13, 2019, the Board approved and accrued an incentive bonus in the amount of $75,000, which was paid during the year ended December 31, 2019. Johan (Thijs) Spoor On January 3, 2016, the Company entered into an employment agreement with its former President and Chief Executive Officer, Johan Spoor. The employment agreement provided for a term expiring January 2, 2019. Although Mr. Spoor’s employment agreement has expired, he remained employed as the Company’s President and Chief Executive Officer under the terms of his prior employment agreement through his resignation as the Company’s President and Chief Executive Officer effective October 8, 2019. Mr. Spoor continues to serve as a director on the Board of the Company. The employment agreement with Mr. Spoor provided for a base salary of $425,000 per year. At the sole discretion of the Board or the Compensation Committee of the Board, following each calendar year of employment, Mr. Spoor was eligible to receive an additional cash bonus based on his attainment of certain financial, clinical development, and/or business milestones to be established annually by the Board or the Compensation Committee. Mr. Spoor was originally entitled to 10-year stock options to purchase 380,000 shares of Common Stock, pursuant to the 2014 Plan. During the year ended December 31, 2017, stock options to purchase 100,000 shares of Common Stock with a strike price of $4.48 per share with a grant date fair value of $386,900 were granted and vested. On September 29, 2017, Mr. Spoor was granted 100,000 shares of restricted Common Stock subject to milestone-based vesting, in satisfaction of the Company’s obligation to issue the additional 280,000 options to Mr. Spoor described above, with an estimated grant date fair value of $425,000. During the year ended December 31, 2018, all 100,000 shares of restricted Common Stock vested. These stock options were cancelled as a result of Mr. Spoor’s resignation. On June 28, 2018, Mr. Spoor was granted and accrued 100,000 shares of restricted Common Stock subject to milestone-based vesting. During the year ended December 31, 2018, 33,333 of these shares of restricted Common Stock vested. During the year ended December 31, 2019, 66,667 of these shares of restricted Common Stock vested. On June 28, 2018, Mr. Spoor was granted 100,000 shares of restricted Common Stock subject to time-based vesting over three years. During the year ended December 31, 2018, 8,333 shares of restricted Common Stock vested. During the year ended December 31, 2019, 33,334 shares of restricted Common Stock vested. The 58,333 unvested shares of restricted Common Stock were forfeited upon Mr. Spoor’s resignation. On June 28, 2018, the Board approved and accrued an incentive bonus in the amount of $212,500, which was paid during the year ended December 31, 2018. On June 13, 2019, Mr. Spoor was granted stock options to purchase 150,000 shares of Common Stock, subject to milestone-based vesting, with a strike price of $1.75 per share. These unvested stock options were cancelled as a result of Mr. Spoor’s resignation. On June 29, 2019, the Company accrued an incentive bonus in the amount of $255,000. Subsequent to Mr. Spoor’s resignation, the Compensation Committee reviewed the accrued bonus and determined that such amount was not owed and the Company, which determination is being challenged by Mr. Spoor. Mr. Spoor received no additional or severance compensation and all unvested stock options and shares of restricted Common Stock granted to Mr. Spoor were cancelled as a result of Mr. Spoor’s resignation. There are 241,667 earned and unissued shares of restricted Common Stock due to Mr. Spoor. Maged Shenouda On September 26, 2017, the Company entered into an employment agreement with Maged Shenouda, pursuant to which Mr. Shenouda served as the Company’s Chief Financial Officer. Mr. Shenouda’s employment agreement provided for the issuance of stock options to purchase 100,000 shares of Common Stock, pursuant to the 2014 Plan, with a strike price of $4.39 per share and a term of ten years. These stock options vested as follows so long as Mr. Shenouda served as either Executive Vice-President of Corporate Development or as Chief Financial Officer: (i) 75% upon FDA acceptance of a U.S. IND application for MS1819, and (ii) 25% upon the Company completing a Phase IIa clinical trial for MS1819. During the year ended December 31, 2018, these stock options vested. On June 28, 2018, Mr. Shenouda was granted stock options to purchase 100,000 shares of Common Stock, pursuant to the 2014 Plan, with a strike price of $3.04 per share and a term of five years, subject to vesting conditions as follows: (i) 50% upon U.S. acceptance of an IND for MS1819, and (ii) 50% upon the first CF patient doses with MS1819 anywhere in the world. During the year ended December 31, 2018, stock options to purchase 50,000 shares of Common Stock, pursuant to the 2014 Plan, vested and approximately $103,650 was recognized and expensed as stock-based compensation. During the year ended December 31, 2019, stock options to purchase 50,000 shares of Common Stock vested due to the first dosing of CF patients with MS1819 anywhere in the world and approximately $103,650 was recognized and expensed as stock-based compensation. On June 28, 2018, the Board approved and accrued an incentive bonus in the amount of $82,500, which was paid during the year ended December 31, 2018. On June 13, 2019, Mr. Shenouda was granted stock options to purchase 100,000 shares of Common Stock, pursuant to the 2014 Plan, with a strike price of $1.75 per share and a term of five years, that vest upon the completion of enrollment of the next trial of MS 1819 in the U.S. These unvested stock options were cancelled as a result of Mr. Shenouda’s resignation. On June 28, 2019, the Compensation Committee approved the accrual of an incentive bonus in the amount of $100,000. Subsequent to Mr. Shenouda’s resignation, the Compensation Committee reviewed the accrued bonus and determined that such amount was not owed, and the Company reversed the accrual in the quarter ended December 31, 2019. Mr. Shenouda resigned from his position as the Company’s Chief Financial Officer effective November 30, 2019. Mr. Shenouda received no additional or severance compensation and all unvested stock options and shares of restricted Common Stock granted to Mr. Shenouda were cancelled as a result of Mr. Shenouda’s resignation. Mr. Shenouda has a period of twelve months following his resignation to exercise all vested stock options.

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	The Company adopted ASU 2016-02, Leases, as of January 1, 2019, using the modified retrospective approach. Prior year financial statements were not recast under the new standard. The Company leases its office and research facilities under operating leases which are subject to various rent provisions and escalation clauses expiring at various dates through 2020. The escalation clauses are indeterminable and considered not material and have been excluded from minimum future annual rental payments. For the years ended December 31, 2019 and 2018, lease expense amounted to $198,061 and $147,051, respectively. The weighted-average remaining lease term and weighted-average discount rate under operating leases at December 31, 2019 were: December 31, 2019 Lease term and discount rate Weighted-average remaining lease term 0.85 years Weighted-average discount rate 6.0 % Maturities of operating lease liabilities at December 31, 2019 were as follows: 2020 87,008 Total lease payments 87,008 Less imputed interest (3,773 ) Present value of lease liabilities $ 83,235

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	The Company is subject to taxation at the federal level in both the United States and France and at the state level in the United States. At December 31, 2019 and 2018, the Company had no tax provision for either jurisdictions. At December 31, 2019 and 2018, the Company had gross deferred tax assets of approximately $16,372,000 and $12,490,000, respectively. As the Company cannot determine that it is more likely than not that the Company will realize the benefit of the deferred tax asset, a valuation allowance of approximately $16,372,000 and $12,490,000, respectively, has been established at December 31, 2019 and 2018. The change in the valuation allowance in 2019 and 2018 was $3,882,000 and $2,572,000, respectively. As of December 31, 2019 and 2018, the significant components of the Company’s net deferred tax assets consisted of: December 31, December 31, 2019 2018 Gross deferred tax assets: Net operating loss carry-forwards $ 16,197,000 $ 12,019,000 Temporary differences: Stock compensation 199,000 303,000 Accruals 136,000 124,000 Other 131,000 44,000 Amortization (291,000 ) - Deferred tax asset valuation allowance (16,372,000 ) (12,490,000 ) Net deferred tax asset $ - $ - Income taxes computed using the federal statutory income tax rate differs from the Company’s effective tax rate primarily due to the following: December 31, December 31, 2019 2018 Income taxes benefit (expense) at statutory rate 21 % 21 % State income tax 14 % 14 % Non-deductible expense (5 %) (6 %) Change in valuation allowance (30 %) (29 %) 0 % 0 % At December 31, 2019, the Company has gross net operating loss (“ NOL Section 382 At December 31, 2019 and 2018, the Company had approximately $19,475,000 and $15,406,000, respectively, in net operating losses which it can carryforward indefinitely to offset against future French income. At December 31, 2019 and 2018, the Company had taken no uncertain tax positions that would require disclosure under ASC 740, Accounting for Income Taxes.

Net Loss per Common Share

Net Loss per Common Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Net Loss per Common Share	Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method. At December 31, 2019, diluted net loss per share did not include the effect of 3,671,055 shares of Common Stock issuable upon the conversion of convertible debt, 5,378,288 shares of Common Stock issuable upon the exercise of outstanding warrants, 632,667 shares of restricted stock not yet issued, and 1,677,500 shares of Common Stock issuable upon the exercise of outstanding options as their effect would be antidilutive during the periods prior to conversion. At December 31, 2018, diluted net loss per share did not include the effect of 3,112,715 shares of Common Stock issuable upon the exercise of outstanding warrants, 416,000 shares of restricted stock not yet issued, and 994,000 shares of Common Stock issuable upon the exercise of outstanding options as their effect would be antidilutive during the periods prior to conversion.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Johan (Thijs) Spoor During the year ended December 31, 2015, the Company employed the services of JIST Consulting (“ JIST On June 29, 2019, the Company accrued an incentive bonus in the amount of $255,000 payable to Mr. Spoor. Subsequent to Mr. Spoor’s resignation, the Compensation Committee reviewed the accrued bonus and determined that such amount was not owed, which determination is being challenged by Mr. Spoor. As a result of management’s determination, the Company reversed the accrual in the quarter ended December 31, 2019. In addition, Mr. Spoor is entitled to 241,667 shares of restricted Common Stock with a grant date fair value of $855,668 that have not been issued. Management is currently negotiating with Mr. Spoor regarding the amounts, if any, that should be paid to Mr. Spoor relating to payments due to JIST, any bonus payable, as well as the equity awards due to Mr. Spoor. Maged Shenouda From October 1, 2016 until his appointment as the Company’s Chief Financial Officer on September 25, 2017, the Company employed the services of Maged Shenouda as a financial consultant. Included in accounts payable at December 31, 2019 and 2018 is $10,000 and $50,000, respectively, for Mr. Shenouda’s services. On November 1, 2019, Mr. Shenouda submitted his resignation as Chief Financial Officer of the Company, effective November 30, 2019. On June 29, 2019, the Company accrued an incentive bonus in the amount of $100,000 payable to Mr. Shenouda. Subsequent to Mr. Shenouda’s resignation, the Compensation Committee reviewed the accrued bonus and determined that such amount should not be paid, and the Company reversed the accrual in the quarter ended December 31, 2019. Christine Rigby-Hutton During the year ended December 31, 2015, the Company's President, Christine Rigby-Hutton, was employed through Rigby-Hutton Management Services (“ RHMS

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Employee Benefit Plans	401(k) Plan The Company sponsors a multiple employer defined contribution benefit plan, which complies with Section 401(k) of the Internal Revenue Code covering substantially all employees of the Company. All employees are eligible to participate in the plan. Employees may contribute from 1% to 100% of their compensation and the Company matches an amount equal to 100% on the first 6% of the employee contribution and may also make discretionary profit-sharing contributions. Employer contributions under this 401(k) plan amounted to $63,109 and $40,901 for the years ended December 31, 2019 and 2018, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Coronavirus Disease (COVID-19) Beginning around January 2020, the COVID-19 outbreak originating in Wuhan, China has spread globally and may impact the Company’s operations and delay current and planned clinical trial operations in Europe and the U.S., including, but not limited to clinical trial recruitment and participation. Given the uncertainty of the situation, the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. The impact of COVID-19 is evolving rapidly and its future effects are uncertain, management is responding to this crisis and anticipates the need to secure additional financing in response to any potential disruptions or delays due to the COVID-19 outbreak. Termination of TransChem License Agreement On March 11, 2020, the Company provided TransChem with sixty (60) days prior written notice of its intent to terminate the TransChem Sublicense Agreement and the licenses granted thereunder. Issuance of shares of Common Stock to Settle Accounts Payable Effective March 11, 2020, The Company issued its outside Board members an aggregate of 105,937 shares of Common Stock for the settlement of accounts payable in the aggregate amount of $131,149. The aggregate effective settlement price was $1.24 per share, and each individual stock issuance was based on the closing stock price of the Common Stock on the initial date the payable was accrued. Benefit of French Tax Credit Received On March 2, 2020, the Company announced that it has benefited from certain tax credits applicable to French technology companies through its wholly-owned subsidiary, AzurRx SAS resulting in a credit of over 1 million Euros in the French Crédit d’impôt Recherche (" CIR LPC Equity Line of Credit In February 2020, the Company issued 150,000 shares of Common Stock in connection with the LPC Purchase Agreement, resulting in gross proceeds to the Company of $144,000. Continued Nasdaq Listing On March 23, 2020, the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (" Nasdaq Notice The Notice has no immediate effect on the continued listing status of the Company's Common Stock on the Nasdaq Capital Market, and, therefore, the Company's listing remains fully effective. The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with all applicable Nasdaq requirements within the allotted compliance periods. To regain compliance, the closing bid price of the Company's Common Stock must be at least $1.00 per share for 10 consecutive business days at some point during the period of 180 calendar days from the date of the Notice, or until September 21, 2020. If the Company does not regain compliance with the minimum bid price requirement by September 21, 2020, Nasdaq may grant the Company a second period of 180 calendar days to regain compliance. To qualify for this additional compliance period, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, other than the minimum bid price requirement. In addition, the Company would also be required to notify Nasdaq of its intent to cure the minimum bid price deficiency. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's Common Stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the minimum bid price requirement during the 180-day compliance period, secure a second period of 180 days to regain compliance, or maintain compliance with the other Nasdaq listing requirements. January 2020 Closings of the Promissory Note Offering On January 2, 2020, January 3, 2020, and January 9, 2020, the Company issued the Note Investors Promissory Notes in the aggregate principal amount of $3,517,700 and Note Warrants to purchase an aggregate of 1,813,257 shares of Common Stock for total net proceeds of $3,240,930. In connection with the three closings in January 2020 of the Promissory On January 9, 2020, the Company concluded the Promissory Note Offering. In aggregate, the Company issued the Note Investors Promissory Notes in the aggregate principal amount of $6,904,000 and Note Warrants to purchase an aggregate of 3,558,795 shares of Common Stock for total net proceeds of $6,234,600. Additionally, the Company issued Placement Agent Warrants to purchase an aggregate of 444,108 shares of Common Stock. On January 2, 2020, the Company repaid the remaining principal balance of $450,000 plus outstanding accrued interest of $104,153 on the ADEC Notes.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Use of Estimates	The accompanying consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill, intangible assets and contingent consideration), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates
Cash and Cash Equivalents	The Company considers all highly liquid investments with maturities of three months or less from date of purchase to be cash equivalents. All cash balances were highly liquid at December 31, 2019 and 2018, respectively.
Concentrations of Credit Risk	Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At December 31, 2019 and 2018, the Company had $0 and $754,261, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions. The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros.
Cyber-Related Fraud	On August 8, 2019, management was advised that it was a victim of a cyber-related fraud whereby a hacker impersonated one of the Company’s key vendors to redirect payments, totaling $418,765. The Company, including the Audit Committee, completed its investigation and is reviewing all available avenues of recovery, including from the Company’s financial institution to recover the payments. As of September 30, 2019, the Company had recovered $50,858 from its financial institution but management is unable to determine the probability of recovering anything further from the cyber-related fraud. Therefore, as of December 31, 2019, the Company recorded a loss of $367,908 which is included in general and administrative (“ G&A
Debt Instruments	Detachable warrants issued in conjunction with debt are measured at their relative fair value, if they are determined to be equity instrument, or their fair value, if they are determined to be liability instruments, and recorded as a debt discount. Conversion features that are in the money at the commitment date constitute a beneficial conversion feature that is measured at its intrinsic value and recognized as debt discount. Debt discount is amortized as interest expense over the maturity period of the debt using the effective interest method. Contingent beneficial conversion features are recognized when the contingency has been resolved.
Debt Issuance Costs	Debt issuance costs are recorded as a direct reduction of the carrying amount of the related debt. Debt issuance costs are amortized over the maturity period of the related debt instrument using the effective interest method.
Equity-Based Payments to Non-Employees	Equity-based payments to non-employees are measured at fair value on the grant date per ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting.
Fair Value Measurements	The Company follows Accounting Standards Codification (“ASC” (“ASC 820” As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period.
Foreign Currency Translation	For foreign subsidiaries with operations denominated in a foreign currency, assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity.
Goodwill and Intangible Assets	Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not recognized any impairment charges through December 31, 2019. Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years In Process Research & Development 12 years License Agreements 5 years
Impairment of Long-lived Assets	The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment (“ASC 360”
Income Taxes	Income taxes are recorded in accordance with ASC 740, Accounting for Income Taxes (“ASC 740” The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At December 31, 2019 and 2018, the Company does not have any significant uncertain tax positions. All tax years are still open for audit.
Leases	Effective January 1, 2019, the Company adopted Accounting Standards Update (“ ASU
Research and Development	Research and development (“ R&D
Stock-based Compensation	The Company’s board of directors (the “ Board (“ASC 718” For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock.
Sublicense Agreement	As more fully discussed in Note 15, the Company entered into a sublicense agreement with TransChem, Inc. (“ TransChem
Subsequent Events	The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements.
Recent Accounting Pronouncements	In January 2017, the FASB issued guidance to simplify the subsequent measurement of goodwill impairment. The new guidance eliminates the two-step process that required identification of potential impairment and a separate measure of the actual impairment. Goodwill impairment charges, if any, would be determined by reducing the goodwill balance by the difference between the carrying value and the reporting unit’s fair value (impairment loss is limited to the carrying value). This standard is effective for annual or any interim goodwill impairment tests beginning after December 15, 2019.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Goodwill and Intangible Assets	Patents 7.2 years In Process Research & Development 12 years License Agreements 15 years

Fair Value Disclosures (Tables)

Fair Value Disclosures (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value of the Company's financial instruments	Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2019: Cash $ 175,796 $ 175,796 $ 175,796 $ - $ 175,796 Other receivables $ 2,637,303 $ - $ - $ 2,637,303 $ 2,637,303 Note payable $ 444,364 $ - $ - $ 444,364 $ 444,364 Convertible debt $ 1,076,938 $ - $ - $ 1,076,938 $ 1,076,938 At December 31, 2018: Cash $ 1,114,343 $ - $ 1,114,343 $ - $ 1,114,343 Other receivables $ 3,172,676 $ - $ - $ 3,172,676 $ 3,172,676 Note payable $ 255,032 $ - $ - $ 255,032 $ 255,032

Other Receivables (Tables)

Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2019
Receivables [Abstract]
Other receivables	December 31, December 31, 2019 2018 R&D tax credits $ 2,566,281 $ 2,162,373 Other 71,022 1,010,303 Total other receivables $ 2,637,303 $ 3,172,676

Property, Equipment, and Leas_2

Property, Equipment, and Leasehold Improvements (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property, equipment and leasehold improvements	December 31, December 31, 2019 2018 Laboratory equipment $ 193,661 $ 190,406 Computer equipment 74,836 75,417 Office equipment 36,703 37,262 Leasehold improvements 35,711 29,163 Total property, plant and equipment 340,911 332,248 Less accumulated depreciation (263,520 ) (203,394 ) Property, plant and equipment, net $ 77,391 $ 128,854

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Common stock issued at signing to Mayoly, subject to vesting $ 1,740,959 Due to Mayoly at 12/31/19 - €400,000 449,280 Due to Mayoly at 12/31/20 - €350,000 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt 1,219,386 $ 3,802,745
Intangible assets	December 31, December 31, 2019 2018 In process research and development $ - $ 416,600 Less accumulated amortization - (157,671 ) In process research and development, net $ - $ 258,929 License agreements $ - $ 3,398,702 Less accumulated amortization - (3,087,154 ) License agreements, net $ - $ 311,548 Patents $ 3,802,745 $ - Less accumulated amortization (395,661 ) - Patents, net $ 3,407,084 $ -
Goodwill	Goodwill Balance at January 1, 2018 $ 2,016,240 Foreign currency translation (91,410 ) Balance at December 31, 2018 1,924,830 Foreign currency translation (38,144 ) Balance at December 31, 2019 $ 1,886,686

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	December 31, December 31, 2019 2018 Trade payables $ 1,683,505 $ 1,532,110 Accrued expenses 71,177 285,061 Accrued payroll - 253,225 Total accounts payable and accrued expenses $ 1,754,682 $ 2,070,396

Convertible Debt (Tables)

Convertible Debt (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible debt	Total Promissory Notes ADEC Notes Total December 31, December 31, December 31, December 31, 2019 2019 2019 2018 Convertible debt $ 3,836,300 $ 3,386,300 $ 450,000 $ - Unamortized debt discount - revalued warrants (118,356 ) - (118,356 ) - Unamortized debt discount - warrants (878,979 ) (878,979 ) - - Unamortized debt discount - BCF (1,307,755 ) (1,307,755 ) - - Unamortized debt discount - debt issuance costs (566,815 ) (566,815 ) - - Accrued interest 112,543 8,390 104,153 - Total convertible debt $ 1,076,938 $ 641,141 $ 435,797 $ -

Other Liabilities (Tables)

Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Other Liabilities [Abstract]
Other liabilities	December 31, December 31, 2019 2018 Due to Mayoly $ 392,989 $ - Lease liabilities 83,235 - $ 476,224 $ -

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Warrants Abstract
Stock warrant transactions	Exercise Weighted Price Per Average Warrants Share Exercise Price Warrants outstanding and exercisable at January 1, 2018 3,371,385 $ 3.17 - $7.37 $ 5.28 Granted during the period 244,400 $ 2.55 - $2.75 $ 2.58 Expired during the period - - - Exercised during the period (503,070 ) $ 2.50 $ 2.50 Warrants outstanding and exercisable at December 31, 2018 3,112,715 $ 2.55 - $7.37 $ 4.83 Warrants outstanding and exercisable at January 1, 2019 3,112,715 $ 2.55 - $7.37 $ 4.83 Granted during the period 2,265,573 $ 1.07 - $2.82 $ 1.15 Expired during the period - - - Exercised during the period - - - Warrants outstanding and exercisable at December 31, 2019 5,378,288 $ 1.25 - $7.37 $ 2.53
Warrants by exercise price	Number of Weighted Average Weighted Shares Under Remaining Contract Average Exercise Price Warrants Life in Years Exercise Price $ 1.07 - $1.99 3,199,475 3.95 $ 2.00 - $2.99 320,063 3.57 $ 3.00 - $3.99 636,972 2.31 $ 4.00 - $4.99 196,632 2.01 $ 5.00 - $5.99 805,476 2.13 $ 6.00 - $6.99 187,750 1.76 $ 7.00 - $7.37 31,920 0.96 Total 5,378,288 3.30 $ 2.53
Warrants, weighted average assumptions	December 31, December 31, 2019 2018 Expected life (in years) 5 5 Volatility 71 - 80 % 84 % Risk-free interest rate 1.64 - 2.37 % 2.70 % Dividend yield - % - %

Stock-Based Compensation Plan (

Stock-Based Compensation Plan (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
Share-based payment weighted average assumptions	December 31, December 31, 2019 2018 Contractual term (in years) 5 - 10 5 Volatility 72% - 75 % 85 % Risk-free interest rate 1.54% - 1.84 % 2.82 % Dividend yield - % - %
Stock option activity	Number Average Remaining Contract Intrinsic of Shares Exercise Price Life in Years Value Stock options outstanding at January 1, 2018 545,000 $ 4.05 7.13 $ - Granted during the period 539,000 $ 3.04 5.00 $ - Expired during the period - - Canceled during the period (90,000 ) $ 3.26 4.41 $ - Exercised during the period - - Stock options outstanding at December 31, 2018 994,000 $ 3.58 5.42 $ - Exercisable at December 31, 2018 749,500 $ 3.74 5.71 $ - Non-vested stock options outstanding at January 1, 2018 387,500 $ 3.89 6.39 $ - Granted during the period 539,000 $ 3.04 5.00 $ - Vested during the period (600,750 ) $ 3.50 5.00 $ - Expired during the period - - Canceled during the period (81,250 ) $ 3.26 4.41 $ - Exercised during the period - - Non-vested stock options outstanding at December 31, 2018 244,500 $ 3.05 4.53 $ - Stock options outstanding at January 1, 2019 994,000 $ 3.58 5.42 $ - Granted during the period 1,193,500 $ 1.44 5.79 $ - Expired during the period - - Canceled during the period (510,000 ) $ 2.80 4.50 $ - Exercised during the period - - Stock options outstanding at December 31, 2019 1,677,500 $ 2.17 5.37 $ - Exercisable at December 31, 2019 794,000 $ 3.36 4.04 $ - Non-vested stock options outstanding at January 1, 2019 244,500 $ 3.05 4.53 $ - Granted during the period 1,193,500 $ 1.44 5.79 $ - Vested during the period (304,500 ) $ 2.79 3.72 $ - Expired during the period - - Canceled during the period (250,000 ) $ 1.75 4.45 $ - Exercised during the period - - Non-vested stock options outstanding at December 31, 2019 883,500 $ 1.33 6.26 $ -

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Operating lease information	December 31, 2019 Lease term and discount rate Weighted-average remaining lease term 0.85 years Weighted-average discount rate 6.0 %
Maturities of operating lease liabilities	2020 87,008 Total lease payments 87,008 Less imputed interest (3,773 ) Present value of lease liabilities $ 83,235

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Deferred tax assets (liabilities)	December 31, December 31, 2019 2018 Gross deferred tax assets: Net operating loss carry-forwards $ 16,197,000 $ 12,019,000 Temporary differences: Stock compensation 199,000 303,000 Accruals 136,000 124,000 Other 131,000 44,000 Amortization (291,000 ) - Deferred tax asset valuation allowance (16,372,000 ) (12,490,000 ) Net deferred tax asset $ - $ -
Income tax reconciliation	December 31, December 31, 2019 2018 Income taxes benefit (expense) at statutory rate 21 % 21 % State income tax 14 % 14 % Non-deductible expense (5 %) (6 %) Change in valuation allowance (30 %) (29 %) 0 % 0 %

Significant Accounting Polici_4

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2019
Patents
Intangible asset, useful life	7 years 2 months 12 days
In Process Research and Development
Intangible asset, useful life	12 years
License Agreements
Intangible asset, useful life	5 years

Significant Accounting Polici_5

Significant Accounting Policies (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Prepaid expenses	$ 595,187	$ 512,982

Fair Value Disclosures (Details

Fair Value Disclosures (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash	$ 175,796	$ 1,114,343	$ 573,471
Other receivables	2,637,303	3,172,676
Notes Payable	444,364	255,032
Convertible Debt	1,076,938	0
Level 1
Cash	175,796	0
Other receivables	0	0
Notes Payable	0	0
Convertible Debt	0	0
Level 2
Cash	175,796	1,114,343
Other receivables	0	0
Notes Payable	0	0
Convertible Debt	0	0
Level 3
Cash	0	0
Other receivables	2,637,303	3,172,676
Notes Payable	444,364	255,032
Convertible Debt	1,076,938	0
Fair Value
Cash	175,796	1,114,343
Other receivables	2,637,303	3,172,676
Notes Payable	444,364	255,032
Convertible Debt	$ 1,076,938	$ 0

Other Receivables (Details)

Other Receivables (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Receivables [Abstract]
R&D tax credits	$ 2,566,281	$ 2,162,373
Other	71,022	1,010,303
Other receivables	$ 2,637,303	$ 3,172,676

Property, Equipment, and Leas_3

Property, Equipment, and Leasehold Improvements (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, equipment and leasehold improvements, gross	$ 340,911	$ 332,248
Less accumulated depreciation	(263,520)	(203,394)
Property, equipment and leasehold improvements, net	77,391	128,854
Laboratory Equipment
Property, equipment and leasehold improvements, gross	193,661	190,406
Computer Equipment
Property, equipment and leasehold improvements, gross	74,836	75,417
Office Equipment
Property, equipment and leasehold improvements, gross	36,703	37,262
Leasehold Improvements
Property, equipment and leasehold improvements, gross	$ 35,711	$ 29,163

Property, Equipment, and Leas_4

Property, Equipment, and Leasehold Improvements (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Depreciation expense	$ 63,096	$ 61,909
Research and Development Expense [Member]
Depreciation expense	42,283	49,316
General and Administrative Expense [Member]
Depreciation expense	$ 20,813	$ 12,593

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details)	Dec. 31, 2019USD ($)
Patents	$ 3,802,745
Common stock issued at signing to Mayoly
Patents	1,740,959
Due to Mayoly at 12/31/19
Patents	449,280
Due to Mayoly at 12/31/20
Patents	393,120
Assumed Mayoly liabilties and forgiveness of Mayoly debt
Patents	$ 1,219,386

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill (Details 1) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
In Process Research and Development
Intangible assets, gross	$ 0	$ 416,600
Less accumulated amortization	0	(157,671)
Intangible assets, net	0	258,929
License Agreements
Intangible assets, gross	0	3,398,702
Less accumulated amortization	0	(3,087,154)
Intangible assets, net	0	311,548
Patents
Intangible assets, gross	3,802,745	0
Less accumulated amortization	(359,661)	0
Intangible assets, net	$ 3,407,084	$ 0

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, beginning	$ 1,924,830	$ 2,016,240
Foreign currency translation	(38,144)	(91,410)
Goodwill, ending	$ 1,886,686	$ 1,924,830

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 384,234	$ 736,537

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Trade payables	$ 1,683,505	$ 1,532,110
Accrued expenses	71,177	285,061
Accrued payroll	0	253,225
Accounts payable, net	$ 1,754,682	$ 2,070,396

Convertible Debt (Details)

Convertible Debt (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Convertible debt, gross	$ 3,836,300	$ 0
Unamortized debt discount - revalued warrants	(118,356)	0
Unamortized debt discount - warrants	(878,979)	0
Unamortized debt discount - BCF	(1,307,755)	0
Unamortized debt discount - debt issuance costs	(566,815)	0
Accrued interest	112,543	0
Convertible debt, net	1,076,938	$ 0
Promissory Notes
Convertible debt, gross	3,386,300
Unamortized debt discount - revalued warrants	0
Unamortized debt discount - warrants	(878,979)
Unamortized debt discount - BCF	(1,307,755)
Unamortized debt discount - debt issuance costs	(566,815)
Accrued interest	8,390
Convertible debt, net	641,141
ADEC Notes
Convertible debt, gross	450,000
Unamortized debt discount - revalued warrants	(118,356)
Unamortized debt discount - warrants	0
Unamortized debt discount - BCF	0
Unamortized debt discount - debt issuance costs	0
Accrued interest	104,153
Convertible debt, net	$ 435,797

Other Liabilities (Details)

Other Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Other Liabilities [Abstract]
Due to Mayoly, current	$ 392,989	$ 0
Lease liabilities, current	83,235	0
Other liabilities, current	$ 476,224	$ 0

Equity, Common Stock and Ince_2

Equity, Common Stock and Incentive Plan (Details Narrative) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Preferred stock shares, par value	$ 0.0001	$ 0.0001
Preferred stock shares, authorized	10,000,000	10,000,000
Common stock shares, par value	$ 0.0001	$ 0.0001
Common stock shares, authorized	150,000,000	100,000,000
Common stock shares, issued	26,800,519	17,704,925
Common stock shares, outstanding	26,800,519	17,704,925

Warrants (Details)

Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Warrants issued and exercisable, beginning	3,112,715	3,371,385
Granted	2,265,573	244,400
Expired	0	0
Exercised	0	(503,070)
Warrants issued and exercisable, ending	5,378,288	3,112,715
Exercise price per share, Expired		$ 0
Exercise price per share, Exercised		2.50
Weighted average exercise price, beginning	$ 4.83	5.28
Weighted average exercise price, Granted	1.15	2.58
Weighted average exercise price warrants, Expired	0	0
Weighted average exercise price warrants, Exercised	0	2.5
Weighted average exercise price, ending	2.53	4.83
Minimum
Exercise price per share, beginning	2.55	3.17
Exercise price per share, Granted	1.07	2.55
Exercise price per share, ending	1.25	2.55
Maximum
Exercise price per share, beginning	7.37	7.37
Exercise price per share, Granted	2.82	2.75
Exercise price per share, ending	$ 7.37	$ 7.37

Warrants (Details 1)

Warrants (Details 1)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Number of shares under warrants | shares	5,378,288
Weighted average remaining contract life in years	3 years 3 months 18 days
Weighted average exercise price	$ 2.53
Warrant 1
Exercise price, minimum	1.07
Exercise price, maximum	$ 1.99
Number of shares under warrants | shares	3,199,475
Weighted average remaining contract life in years	3 years 11 months 12 days
Warrant 2
Exercise price, minimum	$ 2
Exercise price, maximum	$ 2.99
Number of shares under warrants | shares	320,063
Weighted average remaining contract life in years	3 years 6 months 25 days
Warrant 3
Exercise price, minimum	$ 3
Exercise price, maximum	$ 3.99
Number of shares under warrants | shares	636,972
Weighted average remaining contract life in years	2 years 3 months 22 days
Warrant 4
Exercise price, minimum	$ 4
Exercise price, maximum	$ 4.99
Number of shares under warrants | shares	196,632
Weighted average remaining contract life in years	2 years 4 days
Warrant 5
Exercise price, minimum	$ 5
Exercise price, maximum	$ 5.99
Number of shares under warrants | shares	805,476
Weighted average remaining contract life in years	2 years 1 month 17 days
Warrant 6
Exercise price, minimum	$ 6
Exercise price, maximum	$ 6.99
Number of shares under warrants | shares	187,750
Weighted average remaining contract life in years	1 year 9 months 4 days
Warrant 7
Exercise price, minimum	$ 7
Exercise price, maximum	$ 7.37
Number of shares under warrants | shares	31,920
Weighted average remaining contract life in years	11 months 16 days

Warrants (Details 2)

Warrants (Details 2)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Expected life (in years)	5 years	5 years
Volatility		85.00%
Risk-free interest rate		2.82%
Dividend yield	0.00%	0.00%
Minimum
Volatility	71.00%
Risk-free interest rate	1.64%
Maximum
Volatility	80.00%
Risk-free interest rate	2.37%
Warrants
Expected life (in years)	5 years	5 years
Volatility		84.00%
Risk-free interest rate		2.70%
Dividend yield	0.00%	0.00%

Stock Options (Details)

Stock Options (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Expected life (in years)	5 years	5 years
Volatility		85.00%
Risk-free interest rate		2.82%
Dividend yield	0.00%	0.00%
Minimum
Volatility	71.00%
Risk-free interest rate	1.64%
Maximum
Volatility	80.00%
Risk-free interest rate	2.37%
Option | Minimum
Volatility	72.00%
Risk-free interest rate	1.54%
Option | Maximum
Volatility	75.00%
Risk-free interest rate	1.84%

Stock Options (Details 1)

Stock Options (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of Options Outstanding, Beginning Balance	994,000	545,000
Number of Options, Granted	1,193,500	539,000
Number of Options, Expired	0
Number of Options, Exercised	0	0
Number of Options, Canceled	(510,000)	(90,000)
Number of Options, Forfeited	0	0
Number of Options Outstanding, Ending Balance	1,677,500	994,000
Number of Options Exercisable, Ending Balance	794,000	749,500
Weighted-Average Exercise Price Outstanding, Beginning Balance	$ 3.58	$ 4.48
Weighted-Average Exercise Price, Granted	1.44	3.04
Weighted-Average Exercise Price, Expired	0	0
Weighted-Average Exercise Price, Exercised	0	0
Weighted-Average Exercise Price, Canceled	2.80	3.26
Weighted-Average Exercise Price, Forfeited	0	0
Weighted-Average Exercise Price Outstanding, Ending Balance	2.17	3.58
Weighted-Average Exercise Price Exercisable, Ending Balance	$ 5.37	$ 3.74
Weighted-Average Remaining Contractual Term, Outstanding Beginning Balance	5 years 5 months 1 day
Weighted-Average Remaining Contractual Term, Granted	5 years 9 months 15 days	5 years
Weighted-Average Remaining Contractual Term, Canceled	4 years 6 months	4 years 4 months 28 days
Weighted-Average Remaining Contractual Term, Outstanding Ending Balance	5 years 4 months 13 days	5 years 5 months 1 day
Weighted-Average Remaining Contractual Term, Exercisable Ending Balance	4 years 14 days	5 years 8 months 16 days
Nonvested
Number of Options Outstanding, Beginning Balance	244,500	387,500
Number of Options, Granted	1,193,500	539,000
Number of Options, Vested	(304,500)	0
Number of Options, Expired	0	(600,750)
Number of Options, Exercised	0	0
Number of Options, Canceled	(250,000)	(81,250)
Number of Options, Forfeited	0	0
Number of Options Outstanding, Ending Balance	883,500	244,500
Weighted-Average Exercise Price Outstanding, Beginning Balance	$ 3.05	$ 3.89
Weighted-Average Exercise Price, Granted	1.44	3.04
Weighted-Average Exercise Price, Vested	2.79	3.5
Weighted-Average Exercise Price, Expired	0	0
Weighted-Average Exercise Price, Exercised	0	0
Weighted-Average Exercise Price, Canceled	1.75	3.26
Weighted-Average Exercise Price Outstanding, Ending Balance	$ 1.33	$ 3.05
Weighted-Average Remaining Contractual Term, Outstanding Beginning Balance	4 years 6 months 11 days	6 years 4 months 20 days
Weighted-Average Remaining Contractual Term, Granted	5 years 9 months 15 days	5 years
Weighted-Average Remaining Contractual Term, Vested	3 years 8 months 19 days	5 years
Weighted-Average Remaining Contractual Term, Canceled	4 years 5 months 12 days	4 years 4 months 28 days
Weighted-Average Remaining Contractual Term, Outstanding Ending Balance	6 years 3 months 4 days	4 years 6 months 11 days

Interest Expense (Details Narra

Interest Expense (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Interest expense	$ 433,939	$ 101,846
Convertible Notes
Interest expense	425,907	97,837
Miscellaneous Interest Expense
Interest expense	$ 8,032	$ 4,010

Leases (Details)

Leases (Details)	Dec. 31, 2019
Leases [Abstract]
Weighted-average remaining lease term	10 months 6 days
Weighted-average discount rate	6.00%

Leases (Details 1)

Leases (Details 1)	Dec. 31, 2019USD ($)
Leases [Abstract]
2020	$ 87,008
Total lease payments	87,008
Less: imputed interest	(3,773)
Present value of lease liabilities	$ 83,235

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Gross deferred tax assets:
Net operating loss carry-forwards	$ 16,197,000	$ 12,019,000
Stock compensation	199,000	303,000
Accruals	136,000	124,000
Other	131,000	44,000
Amortization	(291,000)	0
Deferred tax asset valuation allowance	(16,372,000)	(12,490,000)
Net deferred tax asset	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income taxes benefit (expense) at statutory rate	21.00%	21.00%
State income tax, net of federal benefit	14.00%	14.00%
Non-deductible expense	(5.00%)	(6.00%)
Change in valuation allowance	(30.00%)	(29.00%)
Total	0.00%	0.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred tax asset valuation allowance	$ (16,372,000)	$ (12,490,000)
Federal
Net operating loss carry-forwards	29,320,000
State
Net operating loss carry-forwards	$ 27,764,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Mr. Shenouda [Member]
Accounts payable	$ 10,000	$ 50,000
Ms. Rigby-Hutton
Accounts payable	38,453
JIST Consulting
Accounts payable	$ 348,400	$ 478,400